Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Afatinib for Patients with Acquired Resistance to EGFR TKIs? Perhaps in Combination with Erbitux, but Is It Tolerable?

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

With the recent approval of afatinib, now becoming commercially available as Gilotrif, there is the potential new strategy for patients with an EGFR mutation who develop acquired resistance to a different EGFR tyrosine kinase inhibitor (TKI) in an earlier line of therapy.  Afatinib was approved as a first line treatment for patients with an EGFR mutation, a setting in which I don't think it represents an especially appealing option, but does it perhaps represent an answer to the common question of how we should best treat patients who develop acquired resistance to another EGFR TKI?

I'd say that as a single agent, the answer is going to me no, except in a small minority of patients.  This question was directly studied in the LUX Lung-1 trial of afatinib vs. placebo in patients who had gone at least 12 weeks with stable disease or a response to Iressa (gefitinib) or Tarceva (erlotinib) previously, and it wasn't a resounding success for afatinib.  While afatinib was associated with a significant improvement in progression-free survival (PFS) of 3.3 vs. 1.1 months, afatinib conferred absolutely no improvement in overall survival (OS), and in fact median OS was more than a month longer in the recipients of placebo.  The better OS in the placebo arm was not a statistically significant difference, but it's not what you hope to see for a new targeted therapy.  Moreover, as discussed in my recent prior post about the potential role of afatinib, its side effect profile can be very challenging, typically worse than Iressa or Tarceva.

Afatinib has been available in an expanded access protocol for several months, and this has given me occasion to give it to several of my own EGFR mutation-positive patients with acquired resistance to Tarceva and those referred from other centers in the region as a potential therapy in this setting. In short, it has never been effective in any of the handful of patients I've treated, and all have experienced more toxicity than they had on Tarceva.  That's just a small sample, but it corroborates the larger experience with single agent afatinib. I know that there are rare patients who benefit, including at least one in the GRACE community, but I think it's fair to say that this is not a realistic expectation.

The combination of afatinib and cetuximab (Erbitux) has looked promising in a small study of 40 evaluable patients, and there are plans for it to be studied in a larger setting.  In the meantime, however, we know that skin side effects for this combination can be quite severe, and Erbitux isn't FDA approved for lung cancer, making it potentially challenging to have it covered by an insurer.  For these reasons of having it relatively unlikely to be covered without a potential/probably expense of thousands of dollars per month for patients and a real concern that it won't be a tolerable combination in a broad population, I don't think it becomes a viable treatment option off protocol without more research, even if it shows promise now.

That's one opinion, and we'll need to see how afatinib is actually integrated into practice once it becomes widely available.  We also don't yet know how it will be priced, which will certainly be a factor in its uptake.

Stay tuned as this story evolves.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on